{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:44:28Z","timestamp":1792525468613,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM131710"],"award-info":[{"award-number":["GM131710"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM107058"],"award-info":[{"award-number":["GM107058"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM121550"],"award-info":[{"award-number":["GM121550"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA295603"],"award-info":[{"award-number":["CA295603"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA262084"],"award-info":[{"award-number":["CA262084"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119414","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:21:49Z","timestamp":1791933709000},"page":"119414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Discovery of YA8026, an optimized human constitutive androstane receptor activator from a novel ML241-derived scaffold"],"prefix":"10.1016","volume":"321","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7598-7992","authenticated-orcid":false,"given":"Yong","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3204-0915","authenticated-orcid":false,"given":"Linhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-0559","authenticated-orcid":false,"given":"Caitlin","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9693-1832","authenticated-orcid":false,"given":"Srilatha","family":"Sakamuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-5314","authenticated-orcid":false,"given":"Wenbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5361-9327","authenticated-orcid":false,"given":"Raquel Gama","family":"Lima Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-6804","authenticated-orcid":false,"suffix":"Jr.","given":"Alexander D.","family":"MacKerell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6224-6888","authenticated-orcid":false,"given":"Hongbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4132-9887","authenticated-orcid":false,"given":"Fengtian","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119414_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1472563","article-title":"Constitutive androstane receptor, liver pathophysiology and chemical contaminants: current evidence and perspectives","volume":"16","author":"De Battistis","year":"2025","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.119414_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119414_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/scipharm88040042","article-title":"The mechanism of action of cyclophosphamide and its consequences for the development of a new generation of oxazaphosphorine cytostatics","volume":"88","author":"Voelcker","year":"2020","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.ejmech.2026.119414_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0163-7258(88)90004-6","article-title":"Metabolism of oxazaphosphorines","volume":"37","author":"Sladek","year":"1988","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119414_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2174\/1381612805666230110215458","article-title":"The chemistry of the metabolites of cyclophosphamide","volume":"5","author":"Ludeman","year":"1999","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2026.119414_bib6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/17425255.4.7.895","article-title":"The pregnane X receptor: from bench to bedside","volume":"4","author":"Ma","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119414_bib7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1681\/ASN.V1281615","article-title":"Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide","volume":"12","author":"Dubourg","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2026.119414_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2012-06-436691","article-title":"The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies","volume":"121","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119414_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1158\/1535-7163.MCT-15-0667","article-title":"Activation of the constitutive androstane receptor increases the therapeutic index of CHOP in lymphoma treatment","volume":"15","author":"Hedrich","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119414_bib10","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1124\/dmd.121.000483","article-title":"Clinical relevance of the constitutive androstane receptor","volume":"50","author":"Stern","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2026.119414_bib11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1042\/bj3300889","article-title":"Protein serine\/threonine phosphatase inhibitors suppress phenobarbital-induced Cyp2b10 gene transcription in mouse primary hepatocytes","volume":"330","author":"Honkakoski","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.119414_bib12","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1124\/mol.64.5.1069","article-title":"Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells","volume":"64","author":"Kobayashi","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119414_bib13","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1074\/jbc.M411318200","article-title":"Novel CAR-mediated mechanism for synergistic activation of two distinct elements within the human cytochrome P450 2B6 gene in HepG2 cells","volume":"280","author":"Swales","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.drudis.2019.01.021","article-title":"Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor","volume":"24","author":"Chai","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119414_bib15","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1021\/acs.jmedchem.5b01891","article-title":"2-(3-Methoxyphenyl)quinazoline derivatives: a new class of direct constitutive androstane receptor (CAR) agonists","volume":"59","author":"Smutny","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.molcel.2004.11.042","article-title":"A structural basis for constitutive activity in the human CAR\/RXR\u03b1 heterodimer","volume":"16","author":"Xu","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119414_bib17","doi-asserted-by":"crossref","first-page":"17277","DOI":"10.1074\/jbc.M300138200","article-title":"Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes","volume":"278","author":"Maglich","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib18","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3390\/cells9112520","article-title":"CITCO as an adjuvant facilitates CHOP-based lymphoma treatment in hCAR-transgenic mice","volume":"9","author":"Kurian","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119414_bib19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/acsmedchemlett.9b00079","article-title":"DL5050, a selective agonist for the human constitutive androstane receptor","volume":"10","author":"Liang","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119414_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejmech.2019.06.031","article-title":"Human constitutive androstane receptor agonist DL5016: a novel sensitizer for cyclophosphamide-based chemotherapies","volume":"179","author":"Liang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib21","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1021\/acs.jmedchem.4c02064","article-title":"Potent and selective human constitutive androstane receptor activator DL5055 facilitates cyclophosphamide-based chemotherapies","volume":"68","author":"Liang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib22","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1021\/acs.jmedchem.2c01140","article-title":"Discovery of novel human constitutive androstane receptor agonists with the imidazo[1,2-a]pyridine structure","volume":"66","author":"Mejdrov\u00e1","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib23","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41467-025-56642-y","article-title":"The hypolipidemic effect of MI-883, the combined CAR agonist\/PXR antagonist, in diet-induced hypercholesterolemia model","volume":"16","author":"Dusek","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119414_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153868","article-title":"Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment","volume":"7","author":"Stern","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2026.119414_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cmdc.201200520","article-title":"Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase","volume":"8","author":"Chou","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119414_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/srep10405","article-title":"Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor","volume":"5","author":"Lynch","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119414_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119414_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000435","article-title":"Computational fragment-based binding site identification by ligand competitive saturation","volume":"5","author":"Guvench","year":"2009","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejmech.2026.119414_bib29","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1021\/acs.jmedchem.4c02007","article-title":"Discovery of small molecules that bind to Son of Sevenless 2 (SOS2)","volume":"68","author":"Zak","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1021\/ol052578p","article-title":"A highly regioselective amination of 6-aryl-2,4-dichloropyrimidine","volume":"8","author":"Peng","year":"2006","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2026.119414_bib31","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.3390\/molecules29246021","article-title":"Regioselective nucleophilic aromatic substitution: theoretical and experimental insights into 4-aminoquinazoline synthesis as a privileged structure in medicinal chemistry","volume":"29","author":"Barbosa","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119414_bib32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1021\/ci100462t","article-title":"Reproducing crystal binding modes of ligand functional groups using Site-Identification by Ligand Competitive Saturation (SILCS) simulations","volume":"51","author":"Raman","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119414_bib33","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/ci500729k","article-title":"Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors","volume":"55","author":"Lakkaraju","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119414_bib34","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1021\/ct500201y","article-title":"Sampling of organic solutes in aqueous and heterogeneous environments using oscillating excess chemical potentials in grand canonical-like Monte Carlo-molecular dynamics simulations","volume":"10","author":"Lakkaraju","year":"2014","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.119414_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bcp.2006.09.022","article-title":"Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series)","volume":"73","author":"Theobald","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119414_bib36","doi-asserted-by":"crossref","first-page":"8689","DOI":"10.1039\/C4OB01377H","article-title":"Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B","volume":"12","author":"Heuson","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41598-021-03885-6","article-title":"Phenethylamine is a substrate of monoamine oxidase B in the paraventricular thalamic nucleus","volume":"12","author":"Obata","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119414_bib38","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0090-9556(25)08459-4","article-title":"Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450","volume":"24","author":"Yu","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2026.119414_bib39","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.1021\/acs.jmedchem.5b01346","article-title":"Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083)","volume":"58","author":"Zhou","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib40","doi-asserted-by":"crossref","first-page":"14146","DOI":"10.1074\/jbc.M212482200","article-title":"A novel distal enhancer module regulated by pregnane X receptor\/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression","volume":"278","author":"Wang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114368","article-title":"Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library","volume":"184","author":"Lynch","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119414_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119414_bib44","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib45","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1021\/acs.jcim.9b00210","article-title":"Optimization and evaluation of site-identification by ligand competitive saturation (SILCS) as a tool for target-based ligand optimization","volume":"59","author":"Ustach","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119414_bib46","doi-asserted-by":"crossref","first-page":"8844","DOI":"10.1039\/D1SC01781K","article-title":"Rapid and accurate estimation of protein-ligand relative binding affinities using site-identification by ligand competitive saturation","volume":"12","author":"Goel","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119414_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejmech.2026.119414_bib48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib49","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/jcc.23067","article-title":"Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations","volume":"33","author":"Yu","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.119414_bib50","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/jcc.21287","article-title":"CHARMM: the biomolecular simulation program","volume":"30","author":"Brooks","year":"2009","journal-title":"J. Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:24:20Z","timestamp":1792524260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":49,"alternative-id":["S0223523426008597"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119414","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of YA8026, an optimized human constitutive androstane receptor activator from a novel ML241-derived scaffold","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119414"}}